Glucotrack, Inc. (NDAQ:GCTK), a medical device and digital health platform company focused on diabetes and prediabetes, announced the completion and positive results of its feasibility study for its implantable continuous glucose monitor technology for patients with Type 1 and Type 2 insulin-dependent diabetes.
This is sponsored content issued on behalf of Glucotrack, Inc., please see full disclaimer here.
Join the discussion: Find out what everybody’s saying about this stock on the Glucotrack, Inc. Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.